India: MSF supports the introduction and roll-out of single-dose treatment for kala azar in Bihar State

Vaishali, Delhi, Nairobi - From this day on, treatment for kala azar will only take two hours. Single-dose liposomal amphotericin B, commonly referred to as SD LAmB, has now been made available in local health centres in Bihar as the preferred treatment for kala azar (visceral leishmaniasis - VL). Bihar is one of the states in India where kala azar is highly endemic.

MSF extends its full support to the government of Bihar in implementing the new treatment protocol of administering single-dose (10mg/kg) LAmB as the preferred first-line medicine to patients diagnosed with kala azar.

This new treatment programme is now available in all government local health facilities in Bihar. The use of single-dose LAmB is a shift from the previous treatment protocol of Miltefosine which needed to be administered orally over a period of 28 days. Due to the distance to health facilities, and climatic, social and economic factors, the number of people unable to follow the treatment for 28 days has been high.

Single-dose LAmB is an effective treatment administered through intravenous infusion, which will be given to the patients over a two-hour period. This makes LAmB a more patient-friendly drug as a single point of care that can be given to all categories of patients, including pregnant women and young children [1] and can be administered at different healthcare levels (local health centres and Hospitals).

“This treatment is free, safe and effective. With only one dose, large numbers of patients affected by this disease that is fatal if left untreated, making it a positive step forward towards elimination of kala azar in the region,” says Nines Lima, MSF’s Tropical Medicine Advisor.

Gradually, all local health centres in the most endemic areas of Bihar will be able to diagnose and treat kala azar patients using single-dose LAmB. This paves the way for providing safer treatment for kala azar and towards achieving elimination by reducing the annual incidence to less than one case per 10,000 at the provincial level.

Transmitted by the bite of a sand fly, kala azar is a vector-borne disease, endemic in 76 countries around the world. Typically, the disease thrives in impoverished areas and is almost always fatal if left untreated. In India, Bihar is the epicentre of kala azar where 33 out of 38 districts are affected. The population at risk is nearly 35 million in approximately 11,500 villages spread over 429 provincial blocks.

MSF has been on the frontline of fighting kala azar in Bihar since 2007, and has treated, free of charge, more than 11,000 patients to date with LAmB and has achieved high cure rate results. The organisation extends its support to the Ministry of Health and Family Welfare (MoHFW), the National Vector Borne Disease Control Programme (NVBDCP), the Rajendra Memorial Research Institute (RMRI), and the Kalacore consortium, in the drive to eliminate kala azar and contribute to improving the health status of at-risk populations living in the endemic areas in India.

  • Since July 2007, MSF has treated over 11,000 kala azar (KA) patients in Bihar with LAmB and has achieved excellent results. SD LAmB is even better as it is easy to administer and takes a shorter period of time to diagnose and treat. This single point of treatment and the fact that SD LAmB will gradually be rolled-out  and be offered at local health centres and hospitals means that more people can be treated. Hence the fight to eliminate KA takes yet a positive step forward.
  • Single-dose LAmB, will be provided free of charge at all levels of care in Bihar, where KA is highly endemic.
  • In Bihar, MSF has been treating patients with LAmB since 2007 with good results. MSF has been conducting field research to find the best treatment options for KA patients. See outcomes on the use of LAmB.
  • Currently, MSF supports a 50-bed kala azar ward inside the Sadar District Hospital in Hajipur, and five primary health centres (PHCs) in Goraul, Vaishali, Mahua, Mahnar and Raghapour, where the single-dose LAmB  is either available or will be made available in the near future. See more.
  • Kala azar disproportionately affects the poorest, most vulnerable communities in Bihar and is transmitted by the bite of a sand fly. The disease usually occurs in villages where houses have mud walls and earthen floors, and cattle and other livestock are kept close to human dwellings. See more.

About MSF in India

MSF is an international, independent, medical humanitarian organisation that delivers emergency aid to people affected by armed conflict, epidemics, exclusion from healthcare and natural disasters. MSF has been working in India since 1999, and provides medical treatment to thousands of patients in Andhra Pradesh, Bihar, Chhattisgarh, Jammu and Kashmir, Maharashtra and Manipur. To support MSF or simply to obtain the latest information on MSF's medical humanitarian work in India and around the world, visit our website

[1]It is to be noted that Miltefosine cannot be given to pregnant women. In women of child-bearing age Miltefosine should not be prescribed unless contraception is ensured during the treatment and for two months after the treatment. In women suffering from PKDL, this period is extended to five months.